Ankündigung • Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution SSY Group Limited has obtained the approval for drug production and registration for Safinamide Mesylate Tablets (100mg and 50mg) from National Medical Products Administration of China (the NMPA), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Safinamide Mesylate Tablet is mainly used in combination therapy for adult patients with primary Parkinson’s disease and symptoms fluctuation, in combination with other drugs for Parkinson’s disease such as levodopa. As stated in the Company’s announcement dated 26 May 2026, the Group’s Safinamide Mesylate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Group has obtained the approval for drug production and registration for Procaterol Hydrochloride Inhalation Solution (0.3ml: 30µg) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Procaterol Hydrochloride Inhalation Solution is mainly used in the relief of various symptoms based on airflow limitation in bronchial asthma, chronic bronchitis and emphysema. Ankündigung • Jun 09
Ssy Group Limited Obtains Approval to Become Market Authorization Holder of Ceftizoxime Sodium for Injection SSY Group Limited has obtained the approval from the National Medical Products Administration of China for the change to become the market authorization holder of Ceftizoxime Sodium for Injection (1g and 0.5g). Ceftizoxime Sodium for Injection is mainly used for the treatment of (1) lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections caused by susceptible bacteria; (2) meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae; and (3) uncomplicated gonorrhea. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Guangce Jiang was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 22
Ssy Group Limited Announces Furosemide Obtains Approval for Registration in China The board of directors of SSY Group Limited is announcing that the Group’s Furosemide has obtained the approval for registration from the National Medical Products Administration of China to become bulk drug for the preparations on the market. As stated in the Company’s announcements dated 30 June 2025 and 27 December 2024 respectively, the Group has obtained the approvals for drug production and registration for Furosemide Tablet and Furosemide Injection from the NMPA. Furosemide is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Mar 27
SSY Group Limited, Annual General Meeting, May 15, 2026 SSY Group Limited, Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai., Hong Kong Ankündigung • Mar 17
SSY Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 SSY Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026 Ankündigung • Mar 06
Ssy Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Levofolinate for Injection (25mg) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Levofolinate for Injection is mainly used for the treatment of gastric cancer and colorectal cancer in combination with 5-fluorouracil. Ankündigung • Feb 16
SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025 SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement. Ankündigung • Jan 28
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for adding 2ml specification for Composite Potassium Hydrogen Phosphate Injection from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Composite Pot potassium Hydrogen Phosphate In injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jan 05
SSY Group Limited Obtains Approval for Drug Production and Registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) (perindopril arginine 10mg, amlodipine besylate 5mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Perindopril Arginines and AmlodipineBylate Tablet is a compound preparation which is mainly used in adult patients whose hypertension is not adequately controlled by monotherapy, or as an alternative therapy for primary hypertension which is under control by combination therapy with the same dose level of perindopril and amlodipine. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Nov 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Tolterodine Tartrate Sustained-Release Capsules (4mg) The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tolterodine Tartrate Sustained-release Capsules (4mg) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tolterodine Tartrates Sustained-release Capsule is mainly used for treatment of overactive bladder. Ankündigung • Oct 20
SSY Group Limited Obtains Approval for Drug Production and Registration for Levlodipine Besilate Tablets The board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation. Levamlodipine besilate Tablet is mainly used for the treatment of hypertension, chronic stable angina and vasospastic angina, which may be used alone or in combination with other drugs. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Sep 01
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Allopurinol Tablet is mainly used for patients with primary or secondary gout, for patients with leukemia, lymphoma and malignant tumors undergoing treatment, and for the treatment of patients with recurrent calcium oxalate stones. As stated in the Company's announcement dated 28 April 2025, the Group's Allopurinol bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Ankündigung • Aug 19
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Morinidazole has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Morinidazole is a nitroimidazole antibiotic which is mainly used for the treatment of appendicitis and pelvic inflammatory disease caused by anaerobic bacteria. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Aug 18
SSY Group Limited to Report First Half, 2025 Results on Aug 28, 2025 SSY Group Limited announced that they will report first half, 2025 results on Aug 28, 2025 Ankündigung • Jul 10
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Potassium Chloride and Sodium Chloride Injection (500Ml and 250Ml) from the National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Pot potassium Chloride and Sodium Chloride Injection (500ml and 250ml) from the National Medical Products Administration of China, both being the second of such approvals for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. Pot potassium Chloride and sodium Chloride Injection is mainly used for the treatment and prevention of hypokalemia, and for the treatment of frequent multifocal premature heart beat or tachycardia caused by digitalis poisoning. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jul 08
SSY Group Limited Announces Update on Innovative Drug Development The board of directors of SSY Group Limited announce the updates on innovative drug development of the Group as follows: Progress on SYN045 tablets: As stated in the Company's announcement dated 3 April 2025, the Group's SYN045 tablets, a Type 1 new drug of chemical drug (a highly selective PGI2 receptor agonist with obvious anti-pulmonary hypertension effects on animals), has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial. The Board announced that, recently, clinical trial of single administration of SYN045 tablets in 50mg and 100mg specifications and multiple administration of 25mg specifications have been completed. The research has shown good results in human pharmacokinetic characteristics and, as compared with drugs of the same drug target, significant improvements in safety and tolerability which are favourable in achieving long-term oral administration. As of now, a total of 18 invention patents has been submitted for SYN045 project, including 5 international invention patents (submitted for international pct applications) and 13 domestic invention patents (in which 5 invention patents related to compounds, crystal forms, preparations, etc. have been granted). Depending on the final results of the Phase I clinical trial, the Group is planning to commence the Phase IIa clinical trial in order to determine the dose-response relationship in the human body and explore the efficacy and safety in the body of patients. The Company will issue an announcement regarding the SYN045 tablets development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Listing Rules’). Progress on other new drug development: The Board is also announced the updates on other new drug development of the Group as follows: Anti-epileptic innovative drug: Being a Type 1 anti-epileptic innovative drug project self-developed by the Group, its drug target is the potassium ion channel KCN Second Quarter /3. Currently, compound screening is commencing, and toxicity assessment is under preparation. Pain treatment innovative drug: Being a Type 1 innovative drug project self-developed by the Group for anti-diabetic peripheral neuropathic pain, its drug target is the adaptor-associated protein kinase 1 (AAK1). Currently, compound screening is commencing. New improved drug: The Group is currently commencing the research on improved formulations of three new drugs, two of which have been completed pharmacokinetic-based prescription studies and the remaining one is planned to submit an Investigational new drug (IND) application this year. With the plan of accelerating the innovative drug development and the progression of the above innovative drug projects, the Company will issue an announcement regarding the innovative drug development as and when appropriate in accordance with the Listing Rules. Ankündigung • Jul 03
SSY Group Limited Obtains Approval for Drug Production and Registration for Paracetamol Granules The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Paracetamol Granules (0.1g each bag) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Paracetamol Granule is a drug for children of which the Group has obtained the exclusive approval among the PRC entities. It is mainly used for fever caused by common cold or influenza in children, and also for relief of mild to moderate pain. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jun 13
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Tranexamic Acid and sodium Chloride Injection is mainly used for the treatment of all kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. Ankündigung • Jun 05
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Gluconate and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cal calcium Gluconate and sodium Chloride Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning. Ankündigung • May 30
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Low Calcium Peritoneal Dialysis Solution (Lactate -G4.25%) (2000ml, with 4.25% glucose). Low Calcium Peritoneal dialysis Solution (Lactate-G4.25%) is mainly used for patients with acute or chronic renal failure who need continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis treatment. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Apr 23
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (I) (Dapagliflozin 10mg and Metformin Hydrochlorides 1,000mg) and Ibuprofen Arginine Granules (0.4g and 0.2g) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation. Dapagliflozin & Metformin Hydrochloride Sustained-release Tablet (I) is mainly used for improving blood sugar control in adult patients with type 2 diabetes, and Ibuprofen Arinine Granule is mainly used for the following symptoms: toothache, dysmenorrhea, pain caused by trauma, joint and ligament pain, back pain, headache, neuralgia, and fever caused by influenza. The Board is also pleased to announce that the Group's Acipimox and Diprophylline have obtained the approvals for registration from the NMPA to become bulk drugs for the preparations on the market. Acipimox is mainly used in the treatment of hypertriglyceridemia and hypercholesterolemia, and Diprophylline is mainly used in The treatment of bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, etc. for relieving wheezing symptoms. Ankündigung • Apr 10
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Felodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Felodipine is mainly used for the treatment of mild to moderate essential hypertension and stable angina. As stated in the Company's announcement dated 30 March 2023, the Group's Felodipines/Felodipine II Sustained-release Controlled-release Tablets (5mg) have been selected in the tender of the National Centralised Medicines Procurement in the PRC. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Apr 01
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Arbidol Hydrochloride Tablets (50mg) from National Medical Products Administration of China, being under type 3 chemical drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. The Group also produces bulk drug of Arbidol Hydrochloride. Arbidol Hydrochloride Tablet is mainly used in the treatment of upper respiratory tract infections caused by influenza A and B viruses, Novel coronavirus pneumonia, and can be used in the treatment of infections caused by SARS coronavirus and avian influenza virus. Ankündigung • Mar 31
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicardipine Hydrochloride Injection (10ml: 10mg) in form of ampoule from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicardipine hydrochloride Injection in form of ampoule is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company's announcement dated 5 March 2025, the Group's Nicardipine Hydrochlorides bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Injection (10ml: 0.42g) in form of ampoul from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Injection in form of ampoule is mainly used in the treatment of metabolic acidosis, alkalinization of urine and intravenous intoxication by certain drugs. Ankündigung • Mar 28
SSY Group Limited, Annual General Meeting, May 16, 2025 SSY Group Limited, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai, Hong Kong Ankündigung • Mar 22
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nimodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nimodipine is a calcium channel blocker, which is mainly used for the treatment of ischemic cerebrovascular disease, migraine, sudden deafness, mild or moderate hypertension, and for the prevention of cerebral vasospasm caused by mild subarachnoid hemorrhage. Ankündigung • Mar 21
SSY Group Limited Obtains Approval for Drug Production and Registration for Voriconazole for Oral Suspension The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Voriconazole for Oral Suspension (45g:3g) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Voriconazole for Oral suspension in oral dosage form, can be used in child aged 2 years or above and adult patients, and is mainly used in the treatment of various fungal infections, including invasive aspergillosis, candidemia and serious infections caused by Candida, Scedosporium and Fusarium, and for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Mar 18
SSY Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 SSY Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Mar 28, 2025 Ankündigung • Mar 14
SSY Group Limited Obtains Approval for Drug Production and Registration for Epinephrine Hydrochloride Injection (1Ml:1Mg) from the National Medical Products Administration of China SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Epinephrine Hydrochloride Injection (1ml:1mg) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Epinephrine hydrochloride Injection is the main rescue drug for cardiopulmonary resuscitation in cardiac arrest, and can be used in the treatment of severe dyspnea caused by bronchospasm, rapid relief of anaphylaxis triggered by substances such as drugs, and prolongation of action time for infiltration anesthesia drugs. As stated in the Company's announcement dated 27 June 2024, the Group's Epinephrine bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Mar 05
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nicardipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nicardipine hydrochloride is mainly used for the treatment of hypertension. Ankündigung • Feb 25
SSY Group Limited Provides an Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid Tablets (0.5g) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tranexamic Acid Tablet is mainly used for various kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Acipimox Capsules (0.25g) from the NMPA, being under type 4 chemical drug, regarded as passing the consistency evaluation and the fourth of such approvals for the PRC entities. Acipimox Capsule is mainly used for reducing triglyceride levels in patients who do not respond adequately to other treatments (such as statins or fibrates). Ankündigung • Feb 24
SSY Group Limited Provides Update on Product Development SSY Group Limited announced that the Group's Piribedil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Piribedil is mainly used for the treatment of Parkinson's disease and circulatory disturbance. Ankündigung • Jan 20
Ssy Group Limited Obtains Approval for Drug Production and Registration for Composite Potassium Hydrogen Phosphate Injection (5Ml) from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Composite Potassium Hydrogen Phosphate Injection (5ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug, regarded as passing the consistency evaluation and the first of such approval for the PRC entities. Composite Potassium Hydrogen Phosphate Injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Vortioxetine Hydrobromide Tablets (5mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Vortioxetine Hydrobromide Tablet is mainly used for the treatment of depression in adults. As stated in the Company's announcement dated 27 December 2023, the Group's Vortioxetine Hydrobromide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Ankündigung • Jan 08
SSY Group Limited Obtains Approval for Drug Production and Registration for Vonoprazan Fumarate Tablets The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Vonoprazan Fumarate Tablets (20mg and 10mg) from National Medical Products Administration of China (the ‘NMPA’), being under type 4 chemical drug and regarded as passing the consistency evaluation. Vonoprazan Fumarate Tablet is mainly used for the treatment of reflux esophagitis. As stated in the Company's announcement dated 16 December 2024, the Group's Vonoprazan Fumarate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Ankündigung • Jan 06
Ssy Group Limited Announces That the Benidipine Hydrochloride Obtained Approval for Registration from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group's Benidipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Benidipine Hydrochloride is mainly used for the treatment of primary hypertension and angina pectoris. Ankündigung • Dec 30
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Nikethamide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nikethamide is a central nervous system stimulant, which is mainly used for the treatment of central respiratory depression and respiratory depression of various causes. Ankündigung • Dec 16
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announce that the Group's Vonoprazan Fumarate has obtained the approval for registration from the National Medical Products Administration of China (the ‘NMPA’) to become a bulk drug for the preparations on the market. Vonoprazan Fumarate is mainly used for the treatment of reflux esophagitis. In addition, the Board is also announced that the Group's Dronedarone Hydrochloride has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Dronedarone Hydrochloride is an antiarrhythmic drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Dec 02
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Compound Sodium Acetate and Glucose Injection (500ml and 200ml) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, and was among the first three PRC manufacturers with approvals for such drug production. Compound sodium Acetate andGlucose Injection is mainly used in replenishing and maintaining water and electrolytes as well as supplying energy when oral administration is not possible or insufficient, and is the latest generation of sugar-containing sodium acetate balanced crystalloid. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Nov 27
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Glycerol Fructose and Sodium Chloride Injection (250ml). Glycerol Fructose and Sodium Chloride Injection is mainly used for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, intracranial inflammation, etc. Ankündigung • Nov 05
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) The board of directors (the "Board") of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Phenylephrine Hydrochloride Injection (1ml:10mg) from National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and
regarded as passing the consistency evaluation. Phenylephrine Hydrochloride Injection is mainly used in maintaining blood pressure during treatment of shock and during anesthesia, and is also used in controlling paroxysmal supraventricular tachycardia. As stated in the Company's announcement dated 23 July 2024, the Group's Phenylephrine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Ankündigung • Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Cycloserine Capsules (0.25g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cycloserine Capsule is mainly used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis which are caused by susceptible tuberculosis bacteria and after ineffective first-line anti-tuberculosis drug treatment. It can also be used for the treatment of acute urinary tract infections caused by susceptible gram-positive bacteria and gram-negative bacteria. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Lornoxicam for injection (8mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Lornoxicam for injection is mainly used for the short-term treatment of adults' acute pain from mild to moderate level which are not suitable for oral drug administration. Ankündigung • Oct 14
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China SSY Group Limited announce that the Group's Cisatracurium Besilate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cisatracurium Besilate is a muscle relaxant which is mainly used for muscle tension, sedation, general anesthesia during tracheal intubation and as an auxiliary medication to general anesthesia. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to HK$4.46, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 31% over the past three years. Recent Insider Transactions • Sep 25
Chairman & CEO recently bought HK$4.8m worth of stock On the 24th of September, Jiguang Qu bought around 1m shares on-market at roughly HK$3.87 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$21m worth in shares. Ankündigung • Sep 09
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Nefopam Hydrochloride Injection (2ml: 20mg), being the first of such approval for the PRC entities. Nefopam Hydrochlorides Injection is mainly used for symptomatic treatment of acute pain, especially for postoperative pain. Recent Insider Transactions • Sep 04
Chairman & CEO recently bought HK$1.5m worth of stock On the 2nd of September, Jiguang Qu bought around 400k shares on-market at roughly HK$3.81 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares. Ankündigung • Sep 02
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil Tablets (5mg) from National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicorandil Tablet is mainly used in the treatment of angina. As stated in the Company's announcement dated 9 October 2023, the Group's Nicorandil bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Reported Earnings • Aug 31
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) First half 2024 results: EPS: HK$0.23 (up from HK$0.21 in 1H 2023). Revenue: HK$3.34b (flat on 1H 2023). Net income: HK$685.7m (up 7.4% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Declared Dividend • Aug 30
First half dividend increased to HK$0.08 Dividend of HK$0.08 is 14% higher than last year. Ex-date: 12th September 2024 Payment date: 27th September 2024 Dividend yield will be 4.7%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (161% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Aug 16
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 SSY Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 Ankündigung • Aug 07
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Entacapone, Levodopa and Carbidopa Tablets (II) (Entacapone 200mg, Levodopa 100mg, Carbidopa 25mg) and Fluvoxamine maleate Tablets (100mg) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Entacapone, LevODopa and Carbidopa TableTS (II) being the first of such approval for the PRC entities. Entacapone, Levomopa and Carbidopa Tablet (II) are mainly used in adult patients with Parkinson's disease who have end-of-dose motor function fluctuations that cannot be controlled by levodopa/dopa decarboxylase (DDC) inhibitor therapy, and Fluvoxamine maleates Tablets are mainly used in the treatment of depression and obsessive-compulsive disorder. As stated in the Company's announcement dated 27 September 2023, the Group's Entacapone bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Lipid Emulsion (10%)/Amino Acids (15) and Glucose (20%) Injection (1000ml and 1500ml) from the NMPA, both being under type 4 chemical Drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. This three-ch chambers-bag injection is mainly used for parenteral nutrition when enteral nutrition is not feasible, insufficient or prohibited. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$3.69, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 20% over the past three years. Ankündigung • Jul 23
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Phenylephrine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Phenylephrine Hydrochloride is mainly used in the treatment of low blood pressure caused by vasodilation during anesthesia. Ankündigung • Jul 16
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Betahistine Mesilate Tablets (6mg) from National Medical Products Administration of China (the "NMPA"), being the first of such approval for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 27 June 2024, the Group's Betahistine Mesilate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Betahistine Mesilate Tablet is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jun 29
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients). In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Esmolol hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jun 24
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Etomidate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Etomidate is mainly used as an anesthetic drug, and is included in the list of controlled category II psychotropic drugs of China. Currently, the Group has held the psychotropic drugs production licences in China and complied with the relevant regulations on production and management. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jun 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride and Sodium Chloride Injection (100ml) from National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Esmolol Hydrochlorides and Sodium Chloride In injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Jun 08
SSY Group Limited Announces Update on Product Development SSY Group Limited announced that the group's Butylphthalide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Butylphthalide is mainly used in the treatment of minor or moderate ischemic stroke (also known as brain attack). Ankündigung • May 29
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration ofChina has approved the addition of 50ml:4.2g specification and passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Sodium Bicarbonate Injection. Sodium Bicarbonate Injection is mainly used in the treatment of metabolic acidosis, alkalinization of urine, treatment of symptoms caused by hyperacidity and treatment of intravenous intoxication by certain drugs. Ankündigung • May 28
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Ondansetron Hydrochloride Injection (4ml:8mg and 2ml:4mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Ondansetron Hydrochloride Injection is mainly used in the control of nausea and vomiting caused by cancer chemotherapy and radiation therapy, and in the prevention and treatment of post-surgery nausea and vomiting. Upcoming Dividend • May 14
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 21 May 2024. Payment date: 04 June 2024. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of Hong Kong dividend payers (7.5%). In line with average of industry peers (3.3%). Ankündigung • Apr 03
SSY Group Limited Provides Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Cefuroxime Axetil for Suspension (0.25g and 0.125g) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, with 0.25g specification being the first and 0.125g specification being the second of such approvals for the PRC entities. Cefuroxime Axetil for Suspension is mainly used in the treatment of infectious diseases caused by susceptible bacteria. In addition, the Board announced that the Group has obtained the approvals for drug production and registration for Lidocaine Hydrochloride Injection (20ml:0.4g, 10ml:0.2g and 5ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 23 January 2024, the Group's Lidocaine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Lidocaine Hydrochloride Injection is a local anesthesia and antiarrhythmic drug which is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block. Recent Insider Transactions • Mar 29
Chairman & CEO recently bought HK$2.5m worth of stock On the 28th of March, Jiguang Qu bought around 500k shares on-market at roughly HK$4.91 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares. Ankündigung • Mar 28
SSY Group Limited, Annual General Meeting, May 17, 2024 SSY Group Limited, Annual General Meeting, May 17, 2024, at 14:00 China Standard Time. Location: Rooms 4902-03, 49th Floor, Central Plaza, 18 Harbour Road Wanchai Hong Kong Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022) Full year 2023 results: EPS: HK$0.44 (up from HK$0.38 in FY 2022). Revenue: HK$6.46b (flat on FY 2022). Net income: HK$1.32b (up 17% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Ankündigung • Mar 27
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 SSY Group Limited announced Final Dividend for the year ended 31 December 2023 of HKD 0.1 per share with Ex-dividend date 21 May 2024; Record date 22 May 2024 & Payment date 04 June 2024. Ankündigung • Mar 21
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Benserazide hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Berazide hydrochloride is a decarboxylase inhibitor, which is mainly used in combination with Levodopa for the treatment of Parkinson's disease. Ankündigung • Mar 16
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 SSY Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024 Ankündigung • Mar 02
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Nicorandil for Injection is a type of lyophilized powder for injection. It is the third approved lyophilized powder for injection products of the Group, and is mainly used for the treatment of unstable angina. Ankündigung • Mar 01
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output. Ankündigung • Feb 28
SSY Group Limited Receives Approval for Gliclazide Tablet The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Gliclazide Tablets (80mg). Gliclazide Tablet is mainly used in adult patients with type 2 diabetes when dietary control, exercise, and weight loss are not enough to control blood sugar level. Ankündigung • Feb 24
SSY Group Limited Provides Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Ringer's Injection (500ml) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Ringer's Injection is mainly used for replenishing extracellular fluid when circulating blood volume and interstitial fluid decrease, and for correction of metabolic acidosis. Ankündigung • Feb 19
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Propofol Medium and Long Chain Fat Emulsion Injection (20ml: 0.2g and 10ml: 0.1g) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and being the first approved fat emulsion ampoule injection product of the Group. Propofol Medium and Long Chain Fat Emulsion Injection is a short-acting intravenous anesthetic for general anesthesia. It is mainly used for induction and maintenance of general anesthesia, sedation of patients undergoing diagnostic procedures and surgeries, and sedation of patients receiving assisted ventilation treatment. Ankündigung • Jan 31
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group's Isoprenaline hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the second of such approval in the PRC. Ankündigung • Jan 24
SSY Group Limited Provides Update on Product Development The board of directors of SSY Group Limited announced that the Group's Lidocaine hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Lidocaine hydro chloride is a local anesthesia and antiarrhythmic drug. It is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block. Ankündigung • Jan 17
Ssy Group Limited Provides Update on Product Development SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Magnesium Sulfate Injection (20ml: 10g, 10ml: 5g and 2ml: 1g) and Vortioxetine Hydrobromide Tablets (10mg) from the National Medical Products Administration of China, being under type 3 chemical drug and type 4 chemical drug respectively, and regarded as passing the consistency evaluation. As an anticonvulsant drug, Magnesium Sulfate Injection is a mainly used in pregnancy-induced hyper-tension for the treatment of pre-eclampsia and eclampsia by reducing blood pressure. Vortioxetine Hydrobromide Tablets is mainly used for the treatment of depression in adults. Ankündigung • Jan 10
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Chlorphenamine Maleate Injection (2ml: 20mg and 1ml: 10mg), in which the 2ml: 20mg specification being the first and 1ml: 10mg specification being the second of respective approvals for the PRC entities. Chlorphenamine Maleate Injection is mainly used in the treatment of allergic rhinitis, and can also be used for colds or sinusitis, mucocutaneous allergy, and control of drug eruption and contact dermatitis. Ankündigung • Jan 05
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Ropivacaine Hydrochloride and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approval for the PRC entities. Ropivacaine Hydro chloride and Sodium Chloride injection is mainly used in local or regional anesthesia and acute pain management for surgery. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Dec 27
SSY Group Limited Provides Update on Product Development The board of directors (the "Board") of SSY Group Limited announce that the Group's Vortioxetine hydrobromide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Vortioxetine hydrobromide is a 5-hydroxytryptamine (5-HT) reuptake inhibitor, and is an agonist, partial agonist or antagonist of certain types of 5-HT receptors. It is mainly used in the treatment of major depressive disorder (MDD) in adults. Recent Insider Transactions • Dec 06
Chairman & CEO recently bought HK$4.7m worth of stock On the 5th of December, Jiguang Qu bought around 1m shares on-market at roughly HK$4.74 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares. Ankündigung • Dec 01
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tedizolid Phosphate Tablets (200mg) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 11 April 2023, the Group's Tedizolid phosphate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Tedizolid Phosphate Tablet is mainly used in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of Gram-positive bacteria (including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, and Enterococcus facadeecalis). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group. Ankündigung • Nov 23
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Tirofiban Hydrochloride and Sodium Chloride Injection (100ml: Tirofiban Hydrochlorides 5mg and Sodium Chloride 0.9g). Tirofiban HydrochlorIDE and Sodium Chloride In injection is mainly used in reducing the rate of thrombotic cardiovascular events (death, myocardial infarction, refractory ischemia or repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Ankündigung • Nov 10
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Pot potassium Chloride Injection (10ml: 1.5g) in form of polypropylene (PP) ampoule, which is the third of such approval for the PRC entities. Pot potassium Chloride In injection is mainly used in the treatment and prevention of hypokalemia (low blood potassium), and in the treatment of premature heart beat or tachycardia (increased heart rate) caused by digitalis poisoning. Ankündigung • Nov 09
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has officially accepted the application for Phase I clinical trial of the Group's SYN-045, a type 1 new drug of chemical drug and being the second of the Group in this type of drug with application submitted and accepted. SYN-045 is a highly selective PGI2 receptor agonist. Currently, based on the Group's preclinical studies in SYN-045, it has shown very high targeting selectivity, obvious anti-pulmonary hypertension effects on animals, and low toxicity which is favorable in achieving long-term oral administration. Ankündigung • Nov 02
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 SSY Group Limited announced that Mr. Feng Hao has resigned as a non-executive Director with effect from 1 November 2023 to devote more time to his other business engagements. Mr. Feng Hao has confirmed that he has no disagreement with the Board and there are no other matters about his resignation that need to be brought to the attention of the shareholders of the company or the Stock Exchange of Hong Kong Limited. Ankündigung • Nov 01
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection The board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Aminophylline Injection (10ml:0.25g and 20ml:0.5g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical new drug and regarded as passing the consistency evaluation. Aminophylline Injection is mainly used in the treatment of acute exacerbation of symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (such as emphysema and chronic bronchitis). From October this year to the date of this announcement, the Group has obtained approvals from the NMPA for preparation products with a total of 8 types with 10 specifications, for 1 bulk pharmaceutical product, and for drug clinical trials with a total of 2 types with 4 specifications. Ankündigung • Oct 31
SSY Group Limited Announces Update on Product Development The board of directors of SSY Group Limited announced that the National Medical Products Administration of China (the "NMPA") has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Metoprolol Tartrate Injection (5ml), which is the third of such approval for the PRC entities. Metoprolol Tartrate injection is mainly used in the treatment of tachycardia (ab normally fast heart rate), and in the prevention and treatment of tachycardia and chest pain after acute myocardial infarction. From October this year to the date of this announcement, the Group has obtained approvals from the NMPA for preparation products with a total of 7 types with 8 specifications, for 1 bulk pharmaceutical product, and for drug clinical trials with a total of 2 types with 4 specifications. 